# Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension

> **NCT07645833** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Rigmor Højland Jensen** · enrollment: 96 (estimated)

## Conditions studied

- Idiopathic Intracranial Hypertension (IIH)

## Interventions

- **DRUG:** Eptinezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07645833
- **Lead sponsor:** Rigmor Højland Jensen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2028-06
- **Final completion:** 2029-01
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645833, "Eptinezumab for Chronic Headache in Idiopathic Intracranial Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07645833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*